FCM
MAZE

Farallon Capital Management’s Maze Therapeutics MAZE Stock Holding History

Farallon Capital Management’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.1M Buy
+373,000
New +$16.5M 0.06% 65

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Farallon Capital Management's MAZE Position: Q1 2026 in Review

Farallon Capital Management opened a new position in Maze Therapeutics (MAZE) in Q1 2026: 373,000 shares worth $11.1M. The stake represents 0.06% of the portfolio and ranks #65 among its holdings.

165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Farallon Capital Management held 373,000 shares of Maze Therapeutics worth $11.1M as of Q1 2026.
  • Maze Therapeutics was a new Farallon Capital Management position in Q1 2026.
  • Maze Therapeutics made up 0.06% of Farallon Capital Management's portfolio in Q1 2026, its #65 holding.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.